Burch S, Bogaards A, Siewerdsen J, Moseley D, Yee A, Finkelstein J, Weersink Robert, Wilson B C, Bisland S K
Ontario Cancer Institute, University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9.
J Biomed Opt. 2005 May-Jun;10(3):034011. doi: 10.1117/1.1921887.
This study represents the first reported use of photodynamic therapy (PDT) for metastatic bone lesions and specifically, as a treatment for spinal metastases. A model of bone metastasis in rat confirmed the efficacy of benzoporphyrin derivative-monoacid-mediated PDT for treating lesions within the spine and appendicular bone. Fluorimetry confirmed the selective accumulation of drug into the tumor(s) at 3 h post-injection. 48 h post-light delivery into the vertebral body of the rat spine loss of bioluminescent signal and histological analyses of sectioned spine confirmed MT-1 tumor cell kill in vivo as previously confirmed in vitro using an established cell viability assay. Porcine vertebrae provided a model comparable to that of human for light propagation and PDT response. Histological examination of vertebrae 48 h post-PDT revealed a necrotic radius of 0.6 cm with an average fluence rate of 4.3 mW/cm2. Non-necrotic tissue damage was evident up to 2 cm out from the treatment fiber. Results support the application of PDT to the treatment of primary or metastatic lesions within bone.
本研究首次报道了光动力疗法(PDT)用于转移性骨病变,特别是作为脊柱转移瘤的一种治疗方法。大鼠骨转移模型证实了苯卟啉衍生物单酸介导的光动力疗法治疗脊柱和附属骨病变的有效性。荧光测定法证实注射后3小时药物在肿瘤中选择性蓄积。在向大鼠脊柱椎体进行光照射48小时后,生物发光信号消失,对脊柱切片进行组织学分析证实MT-1肿瘤细胞在体内被杀死,这与之前使用既定的细胞活力测定法在体外所证实的结果一致。猪椎体为光传播和光动力疗法反应提供了一个与人类相当的模型。光动力疗法后48小时对椎体进行组织学检查显示坏死半径为0.6厘米,平均光通量率为4.3毫瓦/平方厘米。距治疗光纤2厘米外可见非坏死性组织损伤。结果支持光动力疗法应用于治疗骨内原发性或转移性病变。